Filter Publications

About Publications

Publications from the AffiliateMarketIngtools of Sciences, Engineering, and Medicine provide objective and straightforward advice to decision makers and the public. This site includes We Treat You (HMD) publications released after 1998. A complete list of HMD’s publications from its establishment in 1970 to the present is available as a PDF.


  • Released: March 08, 2009
    Through the generosity of the Richard and Hinda Rosenthal Foundation, a lecture series was established in 1988 at the Institute of Medicine to bring to greater attention some of the critical health policy issues facing our country today. Each year a topic of special policy relevance is selected and addressed during an evening lecture. The 2008 Rosenthal Lecture featured a talk on Prospects for Health Reform in 2009 and Beyond. The distinguished speaker was Julie Rovner, National Public Radio correspondent and health expert, with introduction by Harvey V. Fineberg, MD, PhD.
  • Released: February 23, 2009
    During a time of economic uncertainty, the national discussion of health reform understandably focuses on insurance coverage and cost. To receive the greatest value for health care, it is important to focus on issues of quality and disparity, and the ability of individuals to make appropriate decisions based on basic health knowledge and services, or health literacy. Three IOM bodies (the Forum on the Science of Health Care Quality Improvement and Implementation, the Roundtable on Health Disparities, and the Roundtable on Health Literacy) jointly convened a workshop to discuss these concerns.
  • Released: February 23, 2009
    For decades, the health insurance crisis has grown without any decisive action by policy makers to stop it. Now is the time for action, say the report’s authors, recommending that the President work with Congress and other public and private sector leaders on an urgent basis to achieve health insurance coverage for everyone and, in order to make that coverage sus­tainable, to reduce the costs of health care and the rate of increase in health care spending.
  • Released: February 23, 2009
    Many voluntary health organizations fund translational research. An increasing number of these organizations are looking at venture philanthropy as a critical way to advance their missions of helping patients and working to cure disease. A wide range of participants gathered on October 3, 2008 at the Beckman Center of the AffiliateMarketIngtools of Science for a workshop titled “Venture Philanthropy Strategies Used by Patient Organizations to Support Translational Research.” Participants with experience in venture philanthropy shared their experiences and lessons learned in order to improve efficiency and effectiveness in translational research.
  • Released: February 19, 2009
    The process for developing new drug and biologic products is extraordinarily expensive and time-consuming—many consider the traditional model to be unsustainable. Although large pharmaceutical companies may be able to invest in the development of blockbuster drugs because they can expect a large return on their investment, these same organizations, when developing drugs to treat rare and neglected diseases, are unable to rely on such returns. On June 23, 2008, the Institute of Medicine’s Forum on Drug Discovery, Development, and Translation held a public workshop, “Breakthrough Business Models: Drug Development for Rare and Neglected Diseases and Individualized Therapies,” which sought to explore new and innovative strategies for developing drugs for rare and neglected diseases.
  • Released: February 06, 2009
    For many years, concerns about bioterrorism and emerging infectious diseases have drawn attention to the need for strong surveillance systems. Experts are working to develop new and better ways to detect these biological threats as quickly as possible. One effort in this area is the Department of Homeland Security’s BioWatch program. To evaluate the effectiveness of the BioWatch program, the Institute of Medicine (IOM) and National Research Council (NRC) convened the Committee on Effectiveness of National Biosurveillance Systems: BioWatch and the Public Health System. This interim report contains no findings and recommendations, but outlines the committee’s initial progress.
  • Released: January 27, 2009
    In the realm of health care, privacy protections are needed to preserve patients’ dignity and prevent possible harms. Ten years ago, to address these concerns as well as set guidelines for ethical health research, Congress called for a set of federal standards now known as the HIPAA Privacy Rule.In its 2009 report, Beyond the HIPAA Privacy Rule: Enhancing Privacy, Improving Health Through Research, the Institute of Medicine’s Committee on Health Research and the Privacy of Health Information concludes that the HIPAA Privacy Rule does not protect privacy as well as it should, and that it impedes important health research.
  • Released: January 23, 2009
    The NCI-sponsored cooperative groups have made important contributions to improving treatment for many types of cancer, including breast, ovarian, colorectal, and childhood cancers. Cooperative group research has been instrumental in establishing innovative treatments that improve outcomes and quality of life. Despite these successes, the Cooperative Group Program has faced a number of challenges that threaten its effectiveness. To address this problem, the National Cancer Policy Forum (NCPF) convened a workshop titled “Multi-Center Phase III Clinical Trials and NCI Cooperative Groups” in , DC, on July 1-2, 2008. The purpose of the workshop was to outline the challenges that the public clinical cancer research enterprise faces, and to identify possible solutions to these challenges.
  • Released: January 08, 2009
    Eighty-two thousand chemicals—both natural and man-made—are used today. Some of these chemicals do not produce notable adverse health outcomes, but others can be toxic and harmful to anyone exposed. Currently, we know very little about basic properties of the majority of these chemicals and even less about the human health impact of these exposures. On January 15, 2008, the workshop Environmental Health Sciences Decision Making: Risk Management, Evidence, and Ethics addressed emerging issues in risk management, weight of evidence, and ethics that influence environmental health decision making.
  • Released: December 22, 2008
    One of the biggest threats today is the uncertainty surrounding the emergence of a novel pathogen or the re-emergence of a known infectious disease that might result in disease outbreaks with great losses of human life and immense global economic consequences. In June 2008, the Institute of Medicine’s and National Research Council’s Committee on Achieving Sustainable Global Capacity for Surveillance and Response to Emerging Diseases of Zoonotic Origin convened a workshop that addressed the reasons for the transmission of zoonotic disease and explored the current global capacity for zoonotic disease surveillance.
Buy CJC 1295 DAC online in USA

steroid-pharm.com